<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2333">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03076515</url>
  </required_header>
  <id_info>
    <org_study_id>TCH_002</org_study_id>
    <nct_id>NCT03076515</nct_id>
  </id_info>
  <brief_title>Migraine Treatment With Nerivio Migra Neurostimulation Device</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Sham Controlled Multi-center Clinical Trial, Migraine Headache Treatment With Nerivio Migra Neurostimulation Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio
      between treatment and control groups will be 1:1, stratified by center and use of preventive
      medications.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain relief</measure>
    <time_frame>2 hours post treatment</time_frame>
    <description>Percentage of patients reporting freedom from pain (pain grade 0) 2 hours post treatment without rescue medications in at least 50% of treated attacks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Nerivio Migra active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nerivio Migra placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nerivio Migra neurostimulation</intervention_name>
    <description>transcutaneous electrical stimulation</description>
    <arm_group_label>Nerivio Migra active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Nerivio Migra</intervention_name>
    <arm_group_label>Nerivio Migra placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is 18-75 years old.

          2. Patient meeting the ICHD-3 diagnostic criteria for migraine with and without aura.

          3. Patients reporting 2-8 migraine attacks per month.

          4. Patient must be able and willing to comply with the protocol.

          5. Patient must be able and willing to provide written informed consent.

          6. Male or non-pregnant / non-lactating female (NOTE: Females of child bearing potential
             must have a negative pregnancy test) and must be willing to use adequate
             contraceptive means during the study

        Exclusion Criteria:

          1. Has other significant pain problem that in the opinion of the investigator may
             confound the study assessments

          2. Is currently implanted with an electrical and/or neurostimulator device (e.g. cardiac
             pacemaker or defibrillator, vagus nerve neurostimulator, deep brain stimulator,
             spinal stimulator, bone growth stimulator cochlear implant, Sphenopalatine ganglion
             stimulator or Occipital nerve stimulator).

          3. Known uncontrolled epilepsy.

          4. Use of Cannabis including medical use.

          5. Has chronic migraine (more than 15 headache days per month).

          6. Changed usage or dosage of migraine preventive medications in the last two months

          7. Has undergone nerve block (occipital or other) in the head or neck within the last 2
             weeks.

          8. Is participating in any other clinical study. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Grosberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Healthcare Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Solli Brawer, DVM</last_name>
    <email>sollib@theranica.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedStar - Georgetown University Hospital</name>
      <address>
        <city>Washington DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Charles Argoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Healthcare Headache Center</name>
      <address>
        <city>Hartford</city>
        <state>New York</state>
        <zip>06103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Brian M Grosberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzeliya medical Center</name>
      <address>
        <city>Herzliya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maccabi Healthcare neurology clinics</name>
      <address>
        <city>Kefar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bella Gross, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>March 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
